Budget impact analysis of the incorporating of biosimilars in a cancer institute of a philanthropic hospital

Authors

DOI:

https://doi.org/10.30968/rbfhss.2024.153.1130

Abstract

Objective: Global healthcare costs continue to rise annually, and this is a major challenge given the scarce resources and growing prices of innovative drugs. An interesting alternative for reducing costs is the use of biosimilars. This study aimed to assess the financial impact of introducing biosimilars of the drugs adalimumab, rituximab and trastuzumab in a Cancer Institute of a Philanthropic Hospital in the South of the country. Method: This is a retrospective, descriptive study in which a budgetary impact analysis was used to assess the savings generated by the biosimilars standardized at the institution between January 2020 and December 2023. Information on the average cost and monthly consumption of the three biosimilars: adalimumab, rituximab and trastuzumab was used to assess the financial impact. The economic analysis was carried out using the difference between the cost of the biosimilar and the cost of the reference drug, multiplied by annual consumption. Results: It was evidenced during the study period the cost reduction after switching the reference biological with the corresponding biosimilar was R$ 1.540.701,18 (U$ 279.077,14) for adalimumab, R$ 129.824,93 (U$ 23.516,03) for rituximab and R$ 1.604.319,28 (U$ 290.600,70) for trastuzumab. The analysis identified that the standardization of biosimilars at the institution resulted in a global economy of R$ 3.274.845,39 (U$ 593.193,87). Conclusion: The use of biosimilars proved to be a more economical option when compared to the use of the reference biological. In conclusion, the use of biosimilars allows for a considerable reduction in overall treatment costs, especially in the case of innovative and expensive therapies. Therefore, the incorporation of biosimilars is considered an interesting option in the search for the sustainability of health systems.

 

Downloads

Download data is not yet available.

References

Sarder LU, Ahmad S. Emerging role of biosimilars: focus on trastuzumab and metastatic human epidermal growth factor receptor 2-positive breast cancer. Results In Chemistry. 2023; 6: 101055-101056. DOI: 10.1016/j.rechem.2023.101055.

Santos AN, Freitas CAF, Silva RP. Improvement of strategic and pharmacoeconomic management in a private oncology service through the PDCA cycle. BJHR. 2021; 4(6):25814-25827. DOI: 10.34119/bjhrv4n6-178.

Patel KB, Arantes LH Jr, Tang WY, et al. O papel dos biossimilares no cuidado oncológico baseado em valor. Câncer Manag Res. 2018; 10(17):4591-4602. DOI: 10.2147/cmar.s164201.

Simoens ST, Vulto AG. A health economic guide to market access of biosimilars. Expert Opin Biol Ther. 2021; 21(1):9-17. DOI: 10.1080/14712598.2021.1849132.

BRASIL. Resolução da Diretoria Colegiada -RDC RESOLUÇÃO DA DIRETORIA nº 55, de 16 de dezembro de 2010. Dispõe sobre o registro de produtos biológicos novos e produtos biológicos e dá outras providências.

Verrill M, Declerck P, Loibl S, et al. The rise of oncology biosimilars: from process to promise. Future Oncol. 2019; 15(28):3255-3265. DOI: 10.2217/fon-2019-0145.

Guerra LDS; Silva EP; Carnut L. Intercambialidade e aspectos farmacoeconômicos dos medicamentos biossimilares. Jmphc. 2023; 15:1-19. DOI: 10.14295/jmphc.v15.1287.

Agência Nacional de Vigilância Sanitária- ANVISA. Relatório do diálogo setorial: biossimilares-aprimoramento da regulação nacional: SEI/ANVISA - 2550188. Available in: https://antigo.anvisa.gov.br/documents/10181/6511806/Relat%C3%B3rio+Di%C3%A1logo+Setorial+Biossimilares+-+CP+1206.pdf/a011d222-dc9d-4b8b-ae35-d095db17cb87. Accessed on 20 sep 2024.

Medeiros MFB; Okumura, LM; Riveros, BS; et al. Análise de impacto orçamentário: uma revisão prática de conceitos e aplicações para o gestor. J Bras Econ Saúde. 2018; 10(1):75-79. DOI: 10.21115/jbes.v10.n1.p75-9.

Silva EP; Guerra LDS. Revisão integrativa: intercambialidade e aspectos farmacoeconômicos dos medicamentos biossimilares. J Manag Prim Health Care. 2019; 11: 1-3. DOI: 10.14295/jmphc.v11isup.747.

Estado do Rio Grande do Sul. Resolução nº 265/20 - CIB/RS, de 17 de dezembro de 2020. Rede de atenção às pessoas com doenças crônicas não transmissíveis no Rio Grande do Sul: Plano de ação estadual de oncologia. Porto Alegre, RS. Available in: https://saude.rs.gov.br/upload/arquivos/202012/18102403-cibr265-20.pdf. Accessed on 09 sep 2024.

Instituto brasileiro de geografia e estatística (IBGE). Calculadora do IPCA. Available in: https://www.ibge.gov.br/explica/inflacao.php. Accessed on 15 sep 2024.

Banco central do Brasil, Conversor de Moedas. Available in: https://www.bcb.gov.br/conversao. Accessed on 16 sep 2024.

Urru SAM, Alegiani SS, Guella A, et al. Safety of switching between rituximab biosimilars in onco-hematology. Sci Rep. 2021; 11(1):1-5. DOI: 10.1038/s41598-021-85563-1.

Silva MT, Silva EN, Pereira MG. Análise de impacto orçamentário. Epidemiol Serv. 2017; 26(2):421-424. DOI: 10.5123/s1679-49742017000200020.

Teran E; Gomez H; Hannois D; et al. Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment. Lancet Oncol. 2022; 23(7):348-358. DOI: 10.1016/s1470-2045(22)00121-8

Kvien TK; Patel K; Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022; 52: 51939. DOI: 10.1016/j.semarthrit.2021.11.009.

Ngo D; Chen J. A Clinical Review of Biosimilars Approved in Oncology. Ann Pharmacother. 2020; 55(3):362-377. DOI: 10.1177/1060028020944596.

Bennett CL; Schoen MW; Hoque S; et al. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated policy review from the southern network on adverse reactions. Lanceta Oncol. 2020; 21(12):575-588. DOI: 10.1016/s1470-2045(20)30485-x.

Liu IQ. Utilizing oncology biosimilars to minimize the economic burden associated with cancer treatment: managed care considerations. Am J Manag Care. 2021; 27(14):1-2. DOI: 10.37765/ajmc.2021.88734.

Van Adrichem RCS; Voorneveld HJE; Waverijn, et al. The non-medical switch from reference adalimumab to biosimilar adalimumab is highly successful in a large cohort of patients with stable inflammatory rheumatic joint diseases: a real-life observational study. Rheumatol Ther. 2022; 9(4):1109-1118. DOI: 10.1007/s40744-022-00465-6.

Lee, CC; Najafzadeh M; Kesselheim AS; et al. Cost to medicare of delayed adalimumab biosimilar availability. Clin Pharmacol Ther. 2021; 110(4):1050-1056. DOI: 10.1002/cpt.2322.

Chai Q; Wen H; Lang Y; et al. Budget impact analysis of the introduction of a trastuzumab biosimilar for HER2-positive breast cancer in China. Clin Drug Investig. 2022; 42(11):937-947. DOI: 10.1007/s40261-022-01197-9.

Hübel K; Kron F; Lux MP. Biosimilars in oncology: effects on economy and therapeutic innovations. Eur J Cancer. 2020; 139:10-19. DOI: 10.1016/j.ejca.2020.07.037.

Giuliani J; Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 2019; 39(7):3971-3973. DOI: 10.21873/anticanres.13552

Previ TM; Rodrigues AFF. Relação entre trastuzumabe inovador e biossimilar utilizado no tratamento de câncer de mama: estudo transversal de impacto financeiro. In: Pessoa, DLR. Farmácia e suas interfaces com vários saberes. Ponta Grossa: Atena, 2021. p. 1-30.

Barat EC; Arrii ML; Soubieux-bourbon A; et al. Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting. The Breast. 2023; 72:103588. DOI: 10.1016/j.breast.2023.103588.

Published

2024-09-28

How to Cite

1.
BRODT-LEMES ML, BRUSCATO DS, MADRUGA DS, SMANIOTTO J, SAGGIORATO-LUBIAN JR, DE-VILLA LT, CAON S, SILVA TB. Budget impact analysis of the incorporating of biosimilars in a cancer institute of a philanthropic hospital. Rev Bras Farm Hosp Serv Saude [Internet]. 2024Sep.28 [cited 2024Oct.10];15(3):e1130. Available from: https://rbfhss.org.br/sbrafh/article/view/1130

Issue

Section

ORIGINAL ARTICLES